ERS Respiratory Updates

One-day event at the cutting edge of respiratory medicine. Attend in person or access it online as a virtual delegate

ERS Respiratory Updates is a one-day event for respiratory professionals who were unable to attend the ERS International Congress but who want to keep their practice and knowledge up-to-date and at ‘the cutting edge’.

The event will consist of eight comprehensive clinical updates across key fields of respiratory personalised medicine: COPD, asthma, lung cancer, interstitial lung disease (ILD) and pulmonary hypertension. It will give you access to the most current thinking in respiratory clinical medicine, including news, findings and medical advances from the latest ERS International Congress.

The clinical updates will be delivered by prominent international experts in each field and will be followed by Speaker's Corner sessions, at lunchtime and at the end of the day, which will allow you to explore these topics further.

Join us for ERS Respiratory Updates – be at the cutting edge

London: 2 November, 2018 (delivered in English)

View the programme

  • Chairs: Jørgen Vestbo and John Park
  • Each speaker will present for 30 minutes, followed by 10 minutes for questions

Note: you can also be a virtual delegate with our online access option


This event is brought to you in collaboration with the British Thoracic Society (BTS).

Accessible and free for all respiratory professionals

Registration for this event will open soon and will be announced on this webpage. If you cannot attend in person, you will be able to register to join us as an online participant

Earn CME credits

An application will be made to EACCME and EBAP for CME accreditation of this event.

The amount of credits you can receive will correspond to your attendance on the day. Note that you will need to sign the register of attendance on site to ensure that you receive the CME credits.


If you have any queries, please contact

This event is organised by ERS with funding support from GlaxoSmithKline and Novartis.